{"id":"NCT02141516","sponsor":"Novartis","briefTitle":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.","officialTitle":"A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Immunocompromised Patients From 2 to 17 Years of Age Who Are at Increased Risk of Meningococcal Disease Because of Complement Deficiency or Asplenia Compared to Matched Healthy Controls.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2014-05-19","resultsPosted":"2017-02-15","lastUpdate":"2017-02-15"},"enrollment":239,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"rMenB+OMV","otherNames":[]},{"type":"BIOLOGICAL","name":"rMenB+OMV","otherNames":[]},{"type":"BIOLOGICAL","name":"rMenB+OMV","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"EXPERIMENTAL"},{"label":"Group C","type":"ACTIVE_COMPARATOR"}],"summary":"The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement deficiencies or of asplenia or splenic dysfunction. A group of healthy age-matched subjects will be enrolled to serve as a descriptive control for immunogenicity and safety.","primaryOutcome":{"measure":"Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers â‰¥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.","timeFrame":"Day 1 and Day 91 (one month after the second dose of the study vaccine)","effectByArm":[{"arm":"CompDef","deltaMin":0,"sd":null},{"arm":"Asplenia","deltaMin":12,"sd":null},{"arm":"CompDef + Asplenia","deltaMin":9,"sd":null},{"arm":"Healthy","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":20,"countries":["Italy","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":["30068713"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["INJECTION SITE PAIN","FATIGUE","HEADACHE","INJECTION SITE INDURATION","INJECTION SITE SWELLING"]}}